Association between interleukin‑2, interleukin‑10, secretory immunoglobulin A and immunoglobulin G expression
in vaginal fluid and human papilloma virus outcome in patients with cervical lesions

Meng,Jing‑Wei; Song,Jing‑Hui

doi:10.3892/ol.2019.10897

Association between interleukin‑2, interleukin‑10, secretory immunoglobulin A and immunoglobulin G expression in vaginal fluid and human papilloma virus outcome in patients with cervical lesions

Authors:
- Jing‑Wei Meng
- Jing‑Hui Song
View Affiliations

Affiliations: Department of Graduate School, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China, Department of Obstetrics and Gynecology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China
Published online on: September 20, 2019 https://doi.org/10.3892/ol.2019.10897
Pages: 5543-5548

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to investigate the association between a change in vaginal local immunity and human papilloma virus (HPV) infection outcome in patients with cervical lesions, through the study of the expression of vaginal local immune factors, interleukin (IL)‑2, IL‑10, secretory immunoglobulin A (sIgA) and IgG, in patients with different grades of cervical lesions and different degrees of cervical lesions caused by HPV infection prior to and following treatment. The experimental group comprised 136 patients with low‑grade squamous intraepithelial lesions, 236 patients with high‑grade squamous intraepithelial lesions and 133 patients with cervical squamous cell carcinoma, while the control group comprised 100 time‑ and location‑matched healthy women. The concentrations of sIgA, IgG, IL‑2 and IL‑10 in the vaginal lavage fluid, were detected using ELISA prior to treatment and at 3, 6 and 12 months after treatment. Prior to treatment, differences in HPV infection rate and changes in vaginal immune factors between patients with all grades of lesions and controls were statistically significant (P<0.05). Furthermore, IL‑2 and IL‑10 expression levels and the IL‑2/IL‑10 ratio in patients with different grades of lesions, with or without seroconversion, were significantly different to those in controls (P<0.05). However, the differences between changes in IgG and sIgA expression between patients with HPV seroconversion and patients with persistent HPV infection were not statistically significant (P>0.05). The results of the present study suggest that the restoration of humoral immune function promotes HPV seroconversion, and that IL‑2 and IL‑10 levels and their ratio may reflect the severity of cervical lesions and treatment effects to a certain extent.

View Figures

View References

1	Kurman RJ, Carcangiu ML, Herrington CS and Young RH: World Health Organization classification of tumours of female reproductive organs4th. Lyon: IARC Press; pp. 8–25. 2014
2	Tavassoli FA and Devilee P: World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Breast and Female Genital Organs2014
3	Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T and Kjaer SK: Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: A 13-year follow-up. Br J Cancer. 108:234–239. 2013. View Article : Google Scholar : PubMed/NCBI
4	Luhn P, Walker J, Schiffman M, Zuna RE, Dunn ST, Gold MA, Smith K, Mathews C, Allen RA, Zhang R, Wang S and Wentzensen N: The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol. 128:265–270. 2013. View Article : Google Scholar : PubMed/NCBI
5	Griffin C, Harding J and Sutton C: Re: The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOG. 122:10332015. View Article : Google Scholar : PubMed/NCBI
6	Nguyen ML and Flowers L: Cervical cancer screening in immunocompromised women. Obstet Gynecol Clin North Am. 40:339–357. 2013. View Article : Google Scholar : PubMed/NCBI
7	Stanley M: Immunobiology of HPV and HPV vaccines. Gynecol Oncol. 109 (Suppl 2):S15–S21. 2008. View Article : Google Scholar : PubMed/NCBI
8	Prata TT, Bonin CM, Ferreira AM, Padovani CT, Fernandes CE, Machado AP and Tozetti IA: Local immunosuppression induced by high viral load of human papillomavirus: Characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology. 146:113–121. 2015. View Article : Google Scholar : PubMed/NCBI
9	Hwang TS, Jeong JK, Park M, Han HS, Choi HK and Park TS: Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray. Gynecol Oncol. 90:51–56. 2003. View Article : Google Scholar : PubMed/NCBI
10	Pineo CB, Hitzeroth II and Rybicki EP: Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. Plant Biotechnol J. 11:964–975. 2013. View Article : Google Scholar : PubMed/NCBI
11	Chen Y: The changes of local immunity, microcirculation status and serum immune status in patients with cervical cancer. J Hainan Med Univ. 20:226–228. 2014.
12	Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillén D, Alfaro M, Morales J, et al: Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: Critical role of duration of infection. J Natl Cancer Inst. 102:315–324. 2010. View Article : Google Scholar : PubMed/NCBI
13	Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, Levine AM, Darragh TM, Weinberg V and Smith-McCune KK: Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res. 64:6766–74. 2004. View Article : Google Scholar : PubMed/NCBI
14	Baussano I, Ronco G, Segnan N, French K, Vineis P and Garnett GP: HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions. Epidemics. 2:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
15	Torres-Poveda K, Bahena-Román M, Madrid-González C, Burguete-García AI, Bermúdez-Morales VH, Peralta-Zaragoza O and Madrid-Marina V: Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J Clin Oncol. 5:753–763. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kim YT, Lee JM, Hur SY, Cho CH, Kim YT, Kim SC and Kang SB: Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. Int J Cancer. 126:1903–1909. 2010. View Article : Google Scholar : PubMed/NCBI
17	Park JY, Bae J, Lim MC, Lim SY, Lee DO, Kang S, Park SY, Nam BH and Seo SS: Role of high risk-human papilloma virus test in the follow-up of patients who underwent conization of the cervix for cervical intmepithelial neoplasia. J Gynecol Oncol. 20:86–90. 2009. View Article : Google Scholar : PubMed/NCBI
18	Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, Nakanishi T, Kakeda M, Gabazza EC and Mizutani H: Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells. PLoS One. 7:e314652012. View Article : Google Scholar : PubMed/NCBI
19	Vidal AC, Skaar D, Maguire R, Dodor S, Musselwhite LW, Bartlett JA, Oneko O, Obure J, Mlay P, Murphy SK and Hoyo C: IL-10, IL-15, IL-17, and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV16/18 genotypes. Infect Agents Cancer. 10:102015. View Article : Google Scholar : PubMed/NCBI
20	Tang XF, Xu HJ, Guo LH, Gu YF, Tai LZ and Duan Y: Changes and clinical significance of T lymphocyte immune function in cervical cancer patients after operation. Chin J Nosocomiol. 25:1270–1272. 2015.
21	van de Ven AA, Janssen WJ, Schulz LS, van Loon AM, Voorkamp K, Sanders EA, Kusters JG, Nierkens S, Boes M, Wensing AM and van Montfrans JM: Increased prevalence of gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody deficiencies. J Clin Immunol. 34:962–970. 2014. View Article : Google Scholar : PubMed/NCBI
22	de Gruijl TD, Bontkes HJ, Walboomers JM, Schiller JT, Stukart MJ, Groot BS, Chabaud MM, Remmink AJ, Verheijen RH, Helmerhorst TJ, et al: Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer I nst. 89:630–663. 1997. View Article : Google Scholar
23	Lee SR, Zhang SY, Liu DQ and Han CL: Effects of IgG, INF- and CD4+/CD8+T cells on the prognosis of high risk HPV infection in different cervical lesions. Chin Matern Child Health Care. 30:5125–5126. 2015.
24	Passmore JA, Marais DJ, Sampson C, Allan B, Parker N, Milner M, Denny L and Williamson AL: Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia. J Med Virol. 79:1375–1380. 2007. View Article : Google Scholar : PubMed/NCBI
25	Hurlimann J, Dayal R and Gloor E: Immunoglobulins and secretory component in endometrium and cervix. Influence of inflammation and carcinoma. Virchows Arch A Pathol Anat Histol. 377:211–223. 1978. View Article : Google Scholar : PubMed/NCBI
26	Warner RH, Stevens FM and McCarthy CF: Salivary SIgA and SIgA 1 in coeliac disease, inflammatory bowel disease and controls. Ir J Med Sci. 168:33–35. 1999. View Article : Google Scholar : PubMed/NCBI